Aug 23,2017

Amgen Ventures Invests in GNS Healthcare to Advance Applications of its REFS™ Causal Machine Learning and Simulation AI Platforms

GNS Healthcare (GNS), a leading precision medicine company, today announced that it has raised an additional $6 million in equity from Amgen Ventures with participation from existing investor Alexandria Real Estate Equities. The funds will be used to further develop the company�s REFS� causal machine learning and simulation platform and solutions across drug discovery & development, value-based drug solutions, care management, and health system business optimization. With this investment, Amgen Ventures joins other leading biopharma companies Celgene and Zambon Pharmaceuticals, leading health plans Regence Blue Cross Blue Shield (Cambia Health Solutions), and Horizon Blue Cross of NJ and provider Heritage Provider Network, in addition to Mitsui, GHO Capital, and Fort Rock Capital as shareholders of GNS.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Sep 20,2017

Hearst invests $75 million in Moffitt's M2Gen

The investment gives a big boost to M2Gen, a key company in the life sciences sector that Tampa and Florida government leaders are working to foster.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Sep 25,2017

Tempus Announces $60 million in Funding Round

Tempus announced that the two-year old company's total funding reached to $130 million after the company raised $70 million in the Series C.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Dec 22,2017

Acceptance of capital from Japan Post Group

Tokyo-based company, Wellby, which supports the health management of people facing illnesses, has announced that it will carry out a third-party allotment of shares to Japan Post Capital Co., Ltd. and proceed with a partnership with Japan Post Group. By utilizing Japan Post Group's brand and network, Wellby aims to further promote the use of PHR and contribute to medical institutions, regions, and municipalities.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Apr 19,2018

BenevolentAI, which uses AI to develop drugs and energy solutions, nabs $115M at $2B valuation

BenevolventAI announced today that it has raised $115 million to continue developing its core �AI brain� as well as different arms of the company that are using it specifically to break new ground in drug development and more. This venture round values the company at $2.1 billion post-money.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Jul 24,2019

PathAI Receives Strategic Investment from LabCorp

PathAI, a Boston, MA-based provider of artificial intelligence-powered technology for use in pathology research, secured an investment from LabCorp (NYSE: LH), a global life sciences company. The amount of the deal was not disclosed. The company intends to use the funds to expand clinical development of artificial intelligence-enabled computational pathology and advance its eventual integration with clinical laboratories. LabCorp�s investment follows a $60m round of funding into PathAI announced last month, led by global growth equity firm General Atlantic and venture capital firm General Catalyst.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Sep 17,2019

BenevolentAI Announces $90 Million Investment From Temasek

BenevolentAI, the leader in the creation and application of AI and machine learning to transform the way medicines are discovered and developed, today announces that it has raised $90 million from Temasek, a Singapore-headquartered investment company. Raine Advisors acted as exclusive financial advisors to BenevolentAI. The funding will be used to scale and further develop the Benevolent Platform for drug discovery and development. BenevolentAI will continue to advance its growing pipeline of internal drug development programmes and collaborations with strategic partners across its key therapeutic areas. Most recently, BenevolentAI announced long-term collaborations with AstraZeneca and Novartis, which will generate meaningful revenues for BenevolentAI over a multi-year period.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Feb 10,2020

SkinVision has raised an investment from Rubio Impact Ventures

Jones Day advised SkinVision on the investment by Rubio Impact Ventures and existing shareholders.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Feb 25,2020

Qure.ai Raises $16M in Funding

Qure.ai, a Mumbai, India-based healthcare AI company, raised $16M in funding. The round was led by Sequoia India with participation from MassMutual Ventures Southeast Asia (SEA). The company intends to use the funds to drive geographical expansion, expand product portfolio and support regulatory clearances.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Jun 02,2020

UK & Ireland firms receive €40,000 from EIT Health Headstart programme

A total of 16 start-ups from across the UK and Ireland have each been awarded �40,000 and will have access to mentoring and business support through the EIT Health Headstart programme. Each of the teams will get the opportunity to boost their winnings by �10,000 at a pitching competition later this year. One of the startups, VineHealth Digital Limited (UK), allows cancer patients to better track, manage and understand their care with an app. The solution applies machine learning and behavioural science to drive behavioural change. It aims to improve quality of life, promote optimised care delivery and increased survival, and gather patient data that informs more patient-focussed healthcare and academic research.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Subscribe to FUNDING ROUND